FEB 27·Simply Wall St→
Phathom Pharmaceuticals (PHAT) Losses Narrow To US$0.29 EPS And Test Bullish Profitability Narrative
Phathom Pharmaceuticals (PHAT) reported Q4 2025 revenue of US$57.6 million and a narrowed basic EPS loss of US$0.29, with a net loss of US$21.1 million. While revenue growth is strong, trailing 12-month net losses remain substantial at US$221.25 million, raising questions about the company's path to profitability and challenging the bullish narrative that anticipates 25.4% margins within three years. Despite the narrowing quarterly losses, the overall financial health, including negative shareholders' equity, indicates that profitability is still a significant work in progress.
DEC 25·TipRanks▲
Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy’ Stocks
Raymond James analysts are highlighting two "Strong Buy" stocks, Lexeo Therapeutics (LXEO) and Phathom Pharmaceuticals (PHAT), for 2026, anticipating strong performance in the coming year. Lexeo, developing gene therapies for inherited cardiovascular diseases and Alzheimer's, is backed by advancing clinical data and regulatory momentum, with significant revenue projections for its lead asset. Phathom Pharmaceuticals, which focuses on acid-related GI issues, shows promising revenue growth for its approved drug Voquezna, combined with improving cost discipline and new leadership, signaling an attractive long-term risk/reward scenario.
